Apr 18, 2018 Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
Mar 21, 2018 Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301
Mar 15, 2018 Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
Mar 15, 2018 Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting
Dec 14, 2017 Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018